

Global Type 2 Diabetes Mellitus Treatment Market Size study, by Treatment (Drug [Insulin, Sensitizers, SGLT-2, Alpha-Glucosidase Inhibitors, Others], Devices [Blood Glucose Monitoring, Insulin Delivery Devices]), End User, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GFA7C4A1C1E4EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: GFA7C4A1C1E4EN

Abstracts

The Global Type 2 Diabetes Mellitus Treatment Market is valued at approximately USD 18.53 billion in 2023 and is poised to grow at a compound annual growth rate (CAGR) of 9.45% from 2024 to 2032. As the global burden of Type 2 Diabetes escalates, driven by aging populations, sedentary lifestyles, and rising obesity rates, the healthcare industry is increasingly prioritizing integrated treatment modalities to address this chronic metabolic condition. The market is being shaped by a growing reliance on dual therapeutic approaches—pharmacological management and advanced diagnostic and monitoring technologies. With the demand shifting toward patient-centric, real-time disease control, biopharmaceutical firms and medical device manufacturers are embracing innovation to deliver customized insulin regimens, oral antihyperglycemic drugs, and wearable tech-enabled glucose monitoring systems.

The evolution of the treatment paradigm for Type 2 Diabetes has been galvanized by next-generation drugs targeting glucose reabsorption, insulin sensitivity, and pancreatic beta-cell function. SGLT-2 inhibitors, GLP-1 receptor agonists, and combination therapies are seeing a spike in clinical adoption due to their dual cardiovascular and glycemic benefits. Concurrently, digital health integration in diabetes care—via mobile apps, CGM (continuous glucose monitoring), and AI-driven insulin titration—has radically transformed how patients engage with and adhere to treatment. While high drug development costs and reimbursement variability present obstacles, the market is

further bolstered by favorable regulatory policies, rising public-private investment in chronic disease research, and the proliferation of value-based care frameworks encouraging outcomes-focused therapies.

Despite robust market momentum, several challenges continue to hamper widespread adoption of Type 2 Diabetes treatments. Medication adherence remains inconsistent due to complex regimens and side effect profiles, especially in lower-income demographics. Additionally, disparities in healthcare infrastructure, particularly in rural and developing regions, restrict access to advanced diagnostic devices and endocrinologist support. Cost sensitivity is also a key constraint, especially in the insulin segment where out-of-pocket expenses are significant. Moreover, fragmented health data systems limit the real-time feedback loops needed to personalize care. However, as digital ecosystems evolve and cloud-based EHR platforms integrate predictive analytics, opportunities abound to streamline disease management through patient education, behavioral coaching, and proactive intervention models.

Key players in the market are engaging in a high-stakes race to innovate and expand their market share through product launches, mergers, and strategic collaborations. Pharmaceutical companies are intensifying their focus on fixed-dose combination therapies and biosimilars to enhance accessibility. Simultaneously, medical technology firms are pioneering smart insulin pens and patch pumps with Bluetooth connectivity, allowing remote monitoring and physician-guided dosing adjustments. Regulatory bodies such as the FDA and EMA are increasingly supporting fast-track approvals for novel therapies addressing comorbidities like cardiovascular disease and kidney complications associated with diabetes, opening new verticals within the broader treatment ecosystem. Additionally, data-sharing partnerships with health insurers and academic institutions are driving real-world evidence generation, reinforcing clinical outcomes and economic value.

Regionally, North America led the market in 2023 owing to its advanced healthcare infrastructure, high disease prevalence, and strong presence of key players. The U.S. remains a major hub for clinical research and early adoption of insulin delivery systems and glucose monitoring devices. Europe is following closely, supported by robust reimbursement structures and public awareness campaigns promoting early diagnosis and proactive disease management. The Asia Pacific region, meanwhile, is witnessing unprecedented growth propelled by urbanization, dietary shifts, and increased screening efforts. Countries such as India and China are investing heavily in diabetic care infrastructure, which is expected to further accelerate the region's contribution to global market revenues over the forecast period.

Major market player included in this report are:

Novo Nordisk A/S

Sanofi S.A.

Medtronic plc

Eli Lilly and Company

Abbott Laboratories

F. Hoffmann-La Roche Ltd

Dexcom, Inc.

Johnson & Johnson

AstraZeneca PLC

Merck & Co., Inc.

Bayer AG

GlaxoSmithKline plc

Boehringer Ingelheim GmbH

Tandem Diabetes Care, Inc.

Becton, Dickinson and Company

The detailed segments and sub-segment of the market are explained below:

By Treatment

Drug

- Insulin
- Sensitizers
- SGLT-2
- Alpha-Glucosidase Inhibitors
- Others

Devices

- Blood Glucose Monitoring
- Insulin Delivery Devices

By End User

Hospitals

Clinics

Homecare

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET EXECUTIVE SUMMARY

- 1.1. Global T2DM Treatment Market Size & Forecast (2022 – 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Treatment
 - 1.3.2. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Obesity and Sedentary Lifestyles
- 3.1.2. Aging Population and Increasing Diabetes Incidence
- 3.1.3. Shift toward Value-Based and Patient-Centric Care Models

3.2. Market Challenges

- 3.2.1. High Cost of Insulin and Newer Antihyperglycemic Agents
- 3.2.2. Poor Medication Adherence and Complex Regimens
- 3.2.3. Disparities in Access to Advanced Diagnostics in Emerging Markets

3.3. Market Opportunities

- 3.3.1. Expansion of CGM and AI-Driven Digital Health Solutions
- 3.3.2. Growth in Fixed-Dose Combination Therapies and Biosimilars
- 3.3.3. Regulatory Fast-Track Approvals for Cardiovascular-Benefit Drugs

CHAPTER 4. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces
- 4.1.7. Porter's Five Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE

& FORECASTS BY TREATMENT, 2022 – 2032

- 5.1. Segment Dashboard
- 5.2. Global Market: Drug vs. Devices Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.3. Drug Segment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 5.3.1. Insulin
 - 5.3.2. Sensitizers (e.g., Metformin, TZDs)
 - 5.3.3. SGLT-2 Inhibitors
 - 5.3.4. Alpha-Glucosidase Inhibitors
 - 5.3.5. Others
- 5.4. Devices Segment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 5.4.1. Blood Glucose Monitoring
 - 5.4.2. Insulin Delivery Devices

CHAPTER 6. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE & FORECASTS BY END USER, 2022 – 2032

- 6.1. Segment Dashboard
- 6.2. Global Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 6.2.1. Hospitals
 - 6.2.2. Clinics
 - 6.2.3. Homecare
 - 6.2.4. Others

CHAPTER 7. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE & FORECASTS BY REGION, 2022 – 2032

- 7.1. North America T2DM Treatment Market
 - 7.1.1. United States
 - 7.1.1.1. By Treatment Breakdown & Forecasts, 2022 – 2032
 - 7.1.1.2. By End User Breakdown & Forecasts, 2022 – 2032
 - 7.1.2. Canada
- 7.2. Europe T2DM Treatment Market
 - 7.2.1. United Kingdom
 - 7.2.2. Germany
 - 7.2.3. France
 - 7.2.4. Spain
 - 7.2.5. Italy

- 7.2.6. Rest of Europe
- 7.3. Asia Pacific T2DM Treatment Market
 - 7.3.1. China
 - 7.3.2. India
 - 7.3.3. Japan
 - 7.3.4. Australia
 - 7.3.5. South Korea
 - 7.3.6. Rest of Asia Pacific
- 7.4. Latin America T2DM Treatment Market
 - 7.4.1. Brazil
 - 7.4.2. Mexico
- 7.5. Middle East & Africa T2DM Treatment Market
 - 7.5.1. Saudi Arabia
 - 7.5.2. South Africa
 - 7.5.3. Rest of Middle East & Africa

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Novo Nordisk A/S
 - 8.1.2. Sanofi S.A.
 - 8.1.3. Medtronic plc
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Novo Nordisk A/S
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Eli Lilly and Company
 - 8.3.3. Abbott Laboratories
 - 8.3.4. F. Hoffmann-La Roche Ltd
 - 8.3.5. Dexcom, Inc.
 - 8.3.6. Johnson & Johnson
 - 8.3.7. AstraZeneca PLC
 - 8.3.8. Merck & Co., Inc.
 - 8.3.9. Bayer AG
 - 8.3.10. GlaxoSmithKline plc

- 8.3.11. Boehringer Ingelheim GmbH
- 8.3.12. Tandem Diabetes Care, Inc.
- 8.3.13. Becton, Dickinson and Company

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Process
 - 9.1.1. Data Mining
 - 9.1.2. Analysis
 - 9.1.3. Market Estimation
 - 9.1.4. Validation
 - 9.1.5. Publishing
- 9.2. Research Attributes

I would like to order

Product name: Global Type 2 Diabetes Mellitus Treatment Market Size study, by Treatment (Drug [Insulin, Sensitizers, SGLT-2, Alpha-Glucosidase Inhibitors, Others], Devices [Blood Glucose Monitoring, Insulin Delivery Devices]), End User, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GFA7C4A1C1E4EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFA7C4A1C1E4EN.html>